{
  "title": "Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer",
  "abstract": "Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription. Knockdown or pharmacological inhibition of SMYD2 sensitizes breast cancer cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy in part through KMT2D K1330 methylation. Together, our findings uncover a regulatory crosstalk between post-translational modifications that fine-tunes KMT2D function at the chromatin. This provides a rationale for the use of SMYD2 inhibitors in combination with PI3KÎ±/AKT inhibitors in the treatment of ER+/PIK3CA mutant breast cancer.",
  "year": 2024,
  "venue": "Cell Reports",
  "doi": "https://doi.org/10.1016/j.celrep.2024.114174",
  "pdfUrl": "https://www.cell.com/action/showPdf?pii=S2211-1247(24)00502-3",
  "slidesUrl": "/slides/sample-publication.pdf",
  "videoUrl": "https://youtu.be/nQrFzAEBK1c",
  "tags": [
    "Cancer",
    "RNA-seq",
    "ATAC-seq"
  ],
  "featured": false,
  "body": {
    "raw": "\n# Sample Research Publication\n\nThis is the main content of the publication. You can include detailed explanations, methodology, results, and conclusions here.\n\n## Abstract\n\nThis is a placeholder for the abstract content.\n\n## Methodology\n\nDescribe your research methodology here...\n\n## Results\n\nPresent your findings and results...\n\n## Conclusion\n\nSummarize the key takeaways and future work...",
    "code": "var Component=(()=>{var p=Object.create;var o=Object.defineProperty;var u=Object.getOwnPropertyDescriptor;var m=Object.getOwnPropertyNames;var f=Object.getPrototypeOf,b=Object.prototype.hasOwnProperty;var y=(t,e)=>()=>(e||t((e={exports:{}}).exports,e),e.exports),g=(t,e)=>{for(var i in e)o(t,i,{get:e[i],enumerable:!0})},r=(t,e,i,s)=>{if(e&&typeof e==\"object\"||typeof e==\"function\")for(let a of m(e))!b.call(t,a)&&a!==i&&o(t,a,{get:()=>e[a],enumerable:!(s=u(e,a))||s.enumerable});return t};var K=(t,e,i)=>(i=t!=null?p(f(t)):{},r(e||!t||!t.__esModule?o(i,\"default\",{value:t,enumerable:!0}):i,t)),M=t=>r(o({},\"__esModule\",{value:!0}),t);var h=y((v,c)=>{c.exports=_jsx_runtime});var w={};g(w,{default:()=>d,frontmatter:()=>D});var n=K(h()),D={title:\"Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer\",abstract:\"Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription. Knockdown or pharmacological inhibition of SMYD2 sensitizes breast cancer cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy in part through KMT2D K1330 methylation. Together, our findings uncover a regulatory crosstalk between post-translational modifications that fine-tunes KMT2D function at the chromatin. This provides a rationale for the use of SMYD2 inhibitors in combination with PI3K\\u03B1/AKT inhibitors in the treatment of ER+/PIK3CA mutant breast cancer.\",year:2024,venue:\"Cell Reports\",doi:\"https://doi.org/10.1016/j.celrep.2024.114174\",pdfUrl:\"https://www.cell.com/action/showPdf?pii=S2211-1247(24)00502-3\",videoUrl:\"https://youtu.be/nQrFzAEBK1c\",slidesUrl:\"/slides/sample-publication.pdf\",tags:[\"Cancer\",\"RNA-seq\",\"ATAC-seq\"],featured:!1};function l(t){let e={a:\"a\",h1:\"h1\",h2:\"h2\",p:\"p\",span:\"span\",...t.components};return(0,n.jsxs)(n.Fragment,{children:[(0,n.jsxs)(e.h1,{id:\"sample-research-publication\",children:[(0,n.jsx)(e.a,{className:\"anchor\",href:\"#sample-research-publication\",children:(0,n.jsx)(e.span,{className:\"icon icon-link\"})}),\"Sample Research Publication\"]}),`\n`,(0,n.jsx)(e.p,{children:\"This is the main content of the publication. You can include detailed explanations, methodology, results, and conclusions here.\"}),`\n`,(0,n.jsxs)(e.h2,{id:\"abstract\",children:[(0,n.jsx)(e.a,{className:\"anchor\",href:\"#abstract\",children:(0,n.jsx)(e.span,{className:\"icon icon-link\"})}),\"Abstract\"]}),`\n`,(0,n.jsx)(e.p,{children:\"This is a placeholder for the abstract content.\"}),`\n`,(0,n.jsxs)(e.h2,{id:\"methodology\",children:[(0,n.jsx)(e.a,{className:\"anchor\",href:\"#methodology\",children:(0,n.jsx)(e.span,{className:\"icon icon-link\"})}),\"Methodology\"]}),`\n`,(0,n.jsx)(e.p,{children:\"Describe your research methodology here...\"}),`\n`,(0,n.jsxs)(e.h2,{id:\"results\",children:[(0,n.jsx)(e.a,{className:\"anchor\",href:\"#results\",children:(0,n.jsx)(e.span,{className:\"icon icon-link\"})}),\"Results\"]}),`\n`,(0,n.jsx)(e.p,{children:\"Present your findings and results...\"}),`\n`,(0,n.jsxs)(e.h2,{id:\"conclusion\",children:[(0,n.jsx)(e.a,{className:\"anchor\",href:\"#conclusion\",children:(0,n.jsx)(e.span,{className:\"icon icon-link\"})}),\"Conclusion\"]}),`\n`,(0,n.jsx)(e.p,{children:\"Summarize the key takeaways and future work...\"})]})}function d(t={}){let{wrapper:e}=t.components||{};return e?(0,n.jsx)(e,{...t,children:(0,n.jsx)(l,{...t})}):l(t)}return M(w);})();\n;return Component;"
  },
  "_id": "publications/KMT2D.mdx",
  "_raw": {
    "sourceFilePath": "publications/KMT2D.mdx",
    "sourceFileName": "KMT2D.mdx",
    "sourceFileDir": "publications",
    "contentType": "mdx",
    "flattenedPath": "publications/KMT2D"
  },
  "type": "Publication",
  "url": "/publications/KMT2D",
  "slug": "KMT2D"
}